CD64 binding potential does not translate into enhanced therapeutic efficacy for anti-IL-23 antibodies under physiologically relevant conditions

Abstract Background Interleukin (IL)-23 neutralizing antibodies are clinically efficacious but differ in the functionality of their Fc portion. Guselkumab (GUS) and ustekinumab (UST) have a wild-type (WT) Fc portion, permitting native binding to Fc gamma receptors (FcγRs), while risankizumab (RZB) l...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Joel F. Cohen-Solal, Calvin S. Pohl, Sheila M. Cummings, Jeremy P. Gygi, Zhaleh Safikhani, Brigitte Bartocha, Christopher D. Buckley, Yongli Dong, Killian Eyerich, Samuel D. Karsen, Grace R. Lynch, Michael Macoritto, Pierre A. Morisset, Ornella D. Nelson, Timothy Radstake, Florian Rieder, Jocelyn Rivas, John P. Savaryn, Kathleen M. Smith, Madison Stulir, Carmin Szynal, Casey Tylek, Geertruida M. Veldman, Laura G. Wasserman, Susan Westmoreland, Neha Chaudhary, Matthew M. Staron
Format:	Artigo
Jezik:	Inglês
Izdano:	BMC 2026-03-01
Serija:	Molecular Medicine
Teme:	CD64 Crohn’s disease Fc portion FcγRI Guselkumab Inflammatory bowel disease
Online dostop:	https://doi.org/10.1186/s10020-026-01462-z
Oznake:	Označite Brez oznak, prvi označite!